Showing results (11-20 of 80) with videos related to
Sort By:
Pageof 8
Clinical Pharmacology and Therapeutics|November 26, 2025
Endpoint Exposure-Response Analyses in the Presence of Concurrent Dose Modification During Clinical TrialsRui Zhong, Yanguang CaoClinical and Translational Science|April 14, 2026
When Selectivity Increases Uncertainty: Context-Dependent Pharmacology in Antibody Drug DevelopmentXiaozhi Liao, Yanguang CaoAntibodies (Basel, Switzerland)|April 25, 2022
A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph NodesEric Salgado, Yanguang CaoThe Journal of Pharmacology and Experimental Therapeutics|September 28, 2023
Utilizing a Proximity Dependent Labeling Strategy to Study Cancer-Immune Intercellular Interactions In Vitro and In VivoKaitlyn Maffuid, Yanguang CaoEuropean Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2023
Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case studyTimothy Qi, Yanguang CaoClinical Pharmacology and Therapeutics|August 24, 2025
New Approach Methodologies: What Clinical Pharmacologists Should Prepare ForYanguang Cao, William PolacheckScientific Reports|October 8, 2020
Modeling the dynamics of antibody-target binding in living tumorsYu Tang, Yanguang CaoMabs|August 22, 2018
A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal speciesBrian M Maas, Yanguang CaoJournal of Pharmacokinetics and Pharmacodynamics|November 27, 2012
Applications of minimal physiologically-based pharmacokinetic modelsYanguang Cao, William J JuskoJournal of Pharmacokinetics and Pharmacodynamics|August 23, 2014
Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic modelYanguang Cao, William J JuskoPageof 8